Drug profile · INN
loxapine succinate
LOXITANE
loxapine succinate (LOXITANE) is a d2-like dopamine receptor antagonist. Associated with ELITE PHARMACEUTICALS INC /NV/. Route of administration: oral. Current US regulatory status: approved.
Drug details — loxapine succinate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
loxapine succinate (LOXITANE) is a d2-like dopamine receptor antagonist. Associated with ELITE PHARMACEUTICALS INC /NV/. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
D2-like dopamine receptor antagonist
Primary target: D2-like dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is loxapine succinate?
loxapine succinate (LOXITANE) is a d2-like dopamine receptor antagonist. Associated with ELITE PHARMACEUTICALS INC /NV/. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for loxapine succinate?
LOXITANE is a marketed brand name for loxapine succinate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of loxapine succinate?
loxapine succinate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.